Travere Therapeutics Inc [TVTX] stock is trading at $10.19, up 3.03%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TVTX shares have gain 5.60% over the last week, with a monthly amount glided 23.07%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Travere Therapeutics Inc [NASDAQ: TVTX] stock has seen the most recent analyst activity on March 27, 2024, when Guggenheim downgraded its rating to a Neutral. Previously, Citigroup upgraded its rating to Buy on December 05, 2023, and elevated its price target to $10. On November 20, 2023, Citigroup initiated with a Neutral rating and assigned a price target of $7 on the stock. Wells Fargo downgraded its rating to a Equal Weight and decreased its price target to $8 on September 22, 2023. William Blair downgraded its rating to a Mkt Perform. In a note dated July 21, 2023, JP Morgan initiated an Overweight rating and provided a target price of $26 on this stock.
Travere Therapeutics Inc [TVTX] stock has fluctuated between $5.12 and $17.57 over the past year. Currently, Wall Street analysts expect the stock to reach $21.67 within the next 12 months. Travere Therapeutics Inc [NASDAQ: TVTX] shares were valued at $10.19 at the most recent close of the market. An investor can expect a potential return of 112.66% based on the average TVTX price forecast.
Analyzing the TVTX fundamentals
Travere Therapeutics Inc [NASDAQ:TVTX] reported sales of 183.22M for the trailing twelve months, which represents a drop of -27.41%. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -2.18%, Pretax Profit Margin comes in at -2.18%, and Net Profit Margin reading is -0.88%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.96 and Total Capital is -0.81. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 5.45.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.83 points at the first support level, and at 9.46 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.64, and for the 2nd resistance point, it is at 11.08.
Ratios To Look Out For
For context, Travere Therapeutics Inc’s Current Ratio is 2.78. Further, the Quick Ratio stands at 2.75, while the Cash Ratio is 0.25. Considering the valuation of this stock, the price to sales ratio is 4.23, the price to book ratio is 10.47.
Transactions by insiders
Recent insider trading involved Cline Christopher R., CHIEF FINANCIAL OFFICER, that happened on Apr 11 ’24 when 54.0 shares were sold. CHIEF EXECUTIVE OFFICER, Dube Eric M completed a deal on Feb 01 ’24 to sell 19122.0 shares. Meanwhile, SVP, GC & CORPORATE SECRETARY REED ELIZABETH E sold 4764.0 shares on Feb 01 ’24.
